A carregar...
PRSS contributes to cetuximab resistance in colorectal cancer
Cetuximab improves the survival of patients with metastatic colorectal cancer. The main limitation is primary and secondary resistance, the underlying mechanism of which requires extensive investigation. We proved that PRSS expression levels are significantly negatively associated with the sensitivi...
Na minha lista:
| Publicado no: | Sci Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Association for the Advancement of Science
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938705/ https://ncbi.nlm.nih.gov/pubmed/31911942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aax5576 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|